




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C07D 213/00</b>		<b>A2</b>	(11) International Publication Number: <b>WO 00/50398</b>
			(43) International Publication Date: <b>31 August 2000 (31.08.00)</b>
(21) International Application Number: <b>PCT/EP00/01224</b> (22) International Filing Date: <b>15 February 2000 (15.02.00)</b> (30) Priority Data: 99103502.3                      24 February 1999 (24.02.99)                      EP (71) Applicant: <b>F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).</b> (72) Inventors: <b>BOES, Michael; 3550 Jeanne Mance, App. E 1906, Montreal, Quebec H2X 3P7 (CA). GALLEY, Guido; Katzenbuckeweg 14, D-79618 Rheinfelden (DE). GODEL, Thierry; Mittlere Strasse 7, CH-4056 Basel (CH). HOFFMANN, Torsten; Muttenerstrasse 71, CH-4127 Birsfelden (CH). HUNKELER, Walter; Im Stigler 32, CH-4312 Magden (CH). SCHNIDER, Patrick; Stallenrain 7, CH-4104 Oberwil (CH). STADLER, Heinz; Waldhofstrasse 37, CH-4310 Rheinfelden (CH).</b> (74) Agent: <b>POPPE, Regina; Grenzacherstrasse 124, CH-4070 Basel (CH).</b>		(81) Designated States: <b>AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b>  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>	

(54) Title: PHENYL- AND PYRIDINYL DERIVATIVES



## (57) Abstract

The invention relates to compounds of general formula (I), wherein R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; R<sup>1</sup> is hydrogen or halogen; or R and R<sup>1</sup> may be together -CH=CH-CH=CH-; R<sup>2</sup> is hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; R<sup>3</sup> is independently from each other hydrogen, lower alkyl or form a cycloalkyl group; R<sup>4</sup> is hydrogen, halogen, lower alkyl, lower alkoxy, -N(R<sup>5</sup>)<sub>2</sub>, -N(R<sup>5</sup>)S(O)<sub>2</sub>-lower alkyl, -N(R<sup>5</sup>)C(O)R<sup>5</sup> or a cyclic tertiary amine of the group (a); R<sup>5</sup> is, independently from each other, hydrogen, C<sub>3-6</sub>-cycloalkyl, benzyl or lower alkyl; R<sup>6</sup> is hydrogen, hydroxy, lower alkyl, -N(R<sup>5</sup>)CO-lower alkyl, hydroxy-lower alkyl, cyano, -CHO or a 5- or 6 membered heterocyclic group, optionally bonded via an alkylene group, X is -C(O)N(R<sup>5</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>5</sup>)-, -N(R<sup>5</sup>)C(O)-, C(O)O- or -N(R<sup>5</sup>)(CH<sub>2</sub>)<sub>m</sub>-; Y is -(CH<sub>2</sub>)<sub>n</sub>-, -O-, -S-, SO<sub>2</sub>-, -C(O)- or -N(R<sup>5</sup>)-; Z is -N-, -CH= or -C(Cl)-; n is 0 - 4; and, is 1 or 2; and to pharmaceutically acceptable acid addition salts thereof. It has been shown that the compounds of formula (I) have a high affinity to the NK-1 receptor.


**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Phenyl- and pyridinyl derivatives

The present invention relates to compounds of the general formula



wherein

R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl;


5 R<sup>1</sup> is hydrogen or halogen; or

R and R<sup>1</sup> may be together  $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$ ;

R<sup>2</sup> is hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano;

R<sup>3</sup> is, independently from each other, hydrogen, lower alkyl or form a cycloalkyl group;

10 R<sup>4</sup> is hydrogen, halogen, lower alkyl, lower alkoxy,  $-\text{N}(\text{R}^5)_2$ ,  $-\text{N}(\text{R}^5)\text{S}(\text{O})_2$ -lower alkyl,  $-\text{N}(\text{R}^5)\text{C}(\text{O})\text{R}^5$  or a cyclic tertiary amine of the group



R<sup>5</sup> is, independently from each other, hydrogen, C<sub>3-6</sub>-cycloalkyl, benzyl or lower alkyl;

15 R<sup>6</sup> is hydrogen, hydroxy, lower alkyl,  $-\text{N}(\text{R}^5)\text{CO}$ -lower alkyl, hydroxy-lower alkyl, cyano,  $-\text{CHO}$  or a 5- or 6 membered heterocyclic group, optionally bonded via an alkylene group,

X is  $-\text{C}(\text{O})\text{N}(\text{R}^5)-$ ,  $-(\text{CH}_2)_m\text{O}-$ ,  $-(\text{CH}_2)_m\text{N}(\text{R}^5)-$ ,  $-\text{N}(\text{R}^5)\text{C}(\text{O})-$ ,  $-\text{C}(\text{O})\text{O}-$  or  $-\text{N}(\text{R}^5)(\text{CH}_2)_m-$ ;

Y is  $-(\text{CH}_2)_n-$ ,  $-\text{O}-$ ,  $-\text{S}-$ ,  $-\text{SO}_2-$ ,  $-\text{C}(\text{O})-$  or  $-\text{N}(\text{R}^5)-$ ;

Z is  $=\text{N}-$ ,  $-\text{CH}=$  or  $-\text{C}(\text{Cl})=$ ;

5 n is 0 - 4; and

m is 1 or 2;

and to pharmaceutically acceptable acid addition salts thereof.

The compounds of formula I and their salts are characterized by valuable therapeutic properties. It has been surprisingly found that the compounds of the present invention are  
10 antagonists of the Neurokinin 1 (NK-1, substance P) receptor. Substance P is a naturally occurring undecapeptide belonging to the tachykinin family of peptides, the latter being so-named because of their prompt contractile action on extravascular smooth muscle tissue. The receptor for substance P is a member of the superfamily of G protein-coupled receptors.

15 The neuropeptide receptor for substance P (NK-1) is widely distributed throughout the mammalian nervous system (especially brain and spinal ganglia), the circulatory system and peripheral tissues (especially the duodenum and jejunum) and are involved in regulating a number of diverse biological processes.

The central and peripheral actions of the mammalian tachykinin substance P have been  
20 associated with numerous inflammatory conditions including migraine, rheumatoid arthritis, asthma, and inflammatory bowel disease as well as mediation of the emetic reflex and the modulation of central nervous system (CNS) disorders such as Parkinson's disease (Neurosci. Res., 1996, 7, 187-214), anxiety (Can. J. Phys., 1997, 75, 612-621) and depression (Science, 1998, 281, 1640-1645).

25 Evidence for the usefulness of tachykinin receptor antagonists in pain, headache, especially migraine, Alzheimer's disease, multiple sclerosis, attenuation of morphine withdrawal, cardiovascular changes, oedema, such as oedema caused by thermal injury, chronic inflammatory diseases such as rheumatoid arthritis, asthma/bronchial hyperreactivity and other respiratory diseases including allergic rhinitis, inflammatory diseases of the gut  
30 including ulcerative colitis and Crohn's disease, ocular injury and ocular inflammatory diseases reviewed in "Tachykinin Receptor and Tachykinin Receptor Antagonists", J. Auton. Pharmacol., 13, 23-93, 1993.

Furthermore, Neurokinin 1 receptor antagonists are being developed for the treatment of a number of physiological disorders associated with an excess or imbalance of tachykinin, in particular substance P. Examples of conditions in which substance P has been implicated include disorders of the central nervous system such as anxiety, depression  
5 and psychosis (WO 95/16679, WO 95/18124 and WO 95/23798).

The neurokinin-1 receptor antagonists are further useful for the treatment of motion sickness and for treatment induced vomiting.

In addition, in The New England Journal of Medicine, Vol. 340, No. 3 190-195, 1999 has been described the reduction of cisplatin-induced emesis by a selective neurokinin-1-  
10 receptor antagonist.

Furthermore, US 5,972,938 describes a method for treating a psychoimmunologic or a psychosomatic disorder by administration of a tachykinin receptor, such as NK-1 receptor antagonist.

Objects of the present invention are the compounds of formula I and pharmaceutically acceptable salts thereof, the preparation of the above-mentioned compounds,  
15 medicaments containing them and their manufacture as well as the use of the above-mentioned compounds in the control or prevention of illnesses, especially of illnesses and disorders of the kind referred to earlier or in the manufacture of corresponding medicaments.

The most preferred indications in accordance with the present invention are those, which include disorders of the central nervous system or emesis, for example the treatment or prevention of certain depressive disorders by the administration of NK-1 receptor antagonists. A major depressive episode has been defined as being a period of at least two weeks during which, for most of the day and nearly every day, there is either depressed  
20 mood or the loss of interest or pleasure in all, or nearly all activities.

The following definitions of the general terms used in the present description apply irrespective of whether the terms in question appear alone or in combination.

As used herein, the term "lower alkyl" denotes a straight- or branched-chain alkyl group containing from 1-7 carbon atoms, for example, methyl, ethyl, propyl, isopropyl,  
30 n-butyl, i-butyl, t-butyl and the like.

Preferred lower alkyl groups are groups with 1-4 carbon atoms.

The term "lower alkoxy" denotes a group wherein the alkyl residues are as defined above, and which is attached via an oxygen atom.

The term "halogen" denotes chlorine, iodine, fluorine and bromine.

5 The term "cycloalkyl" denotes a saturated carbocyclic group, containing 3-6 carbon atoms.

The term "cyclic tertiary amine" denotes, for example, pyrrol-1-yl, imidazol-1-yl, piperidin-1-yl, piperazin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, 1-oxo-thiomorpholin-4-yl or 1,1-dioxo-thiomorpholin-4-yl.

10 The term "5 or 6 membered heterocyclic group" denotes, for example pyridinyl, pyrimidinyl, oxadiazolyl, triazolyl, tetrazolyl, thiazolyl, thienyl, furyl, pyranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, piperazinyl or piperidyl.

The term "pharmaceutically acceptable acid addition salts" embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic  
15 acid, tartaric acid, methanesulfonic acid, p-toluenesulfonic acid and the like.

Exemplary preferred are compounds, in which Y is -C(O)- and R<sup>4</sup> is 4-methylpiperazinyl, for example the following compounds:

N-[2-Benzoyl-4-(4-methyl-piperazin-1-yl)-phenyl]-2-(3,5-bis-trifluoromethyl-phenyl)isobutyramide,

20 4-Benzoyl-N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-nicotinamide and

N-(3,5-Bis-trifluoromethyl-benzyl)-4-(2-chloro-benzoyl)-N-methyl-6-(4-methyl-piperazin-1-yl)nicotinamide.

Further preferred are compounds, in which Y is -O- and R<sup>4</sup> is hydrogen, morpholinyl  
25 or 4-methylpiperazinyl. Examples of such compounds are:

2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(2-phenoxy-phenyl)-isobutyramide,

2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(2-o-tolyloxy-phenyl)-isobutyramide,

30 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[2-(2,4-dichloro-phenoxy)-phenyl]-N-methyl-isobutyramide,

N-(3,5-Bis-trifluoromethyl-benzyl)-N-methyl-6-morpholin-4-yl-4-phenoxy-nicotinamide,

N-(3,5-Bis-trifluoromethyl-benzyl)-4-(2-chloro-phenoxy)-N-methyl-6-morpholin-4-yl-nicotinamide,

N-(3,5-Bis-trifluoromethyl-benzyl)-4-(2-chloro-phenoxy)-N-methyl-6-(4-methyl-piperazin-1-yl)-nicotinamide and

5 N-(3,5-Bis-trifluoromethyl-benzyl)-N-methyl-6-morpholin-4-yl-4-o-tolyloxy-nicotinamide.

Further preferred are compounds, in which Y is  $-N(CH_3)-$  and  $R^4$  is hydrogen, for example the following compounds:

2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-[2-(methyl-phenyl-amino)-phenyl]-propionamide,


2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-[2-(methyl-phenyl-amino)-phenyl]-isobutyramide,

2-(3,5-Bis-trifluoromethyl-phenyl)-N-[2-(methyl-phenyl-amino)-phenyl]-acetamide and


15 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-[2-(methyl-phenyl-amino)-phenyl]-acetamide.

The present compounds of formula I and their pharmaceutically acceptable salts can be prepared by methods known in the art, for example, by processes described below, which process comprises


20 a) reacting a compound of formula



with a compound of formula




to a compound of formula




wherein  $R^1$  -  $R^5$ ,  $R$ ,  $Y$ ,  $Z$  and  $n$  have the significances given above,

or


- 5 b) reacting a compound of formula



with a compound of formula



to give a compound of formula




10


wherein  $R^1$  -  $R^5$ ,  $R$ ,  $Z$ ,  $Y$  and  $n$  have the significances given above, or



c) reducing a compound of formula




to a compound of formula




5 wherein the definitions of substituents are given above, or


d) reacting a compound of formula



with a compound of formula




10 to a compound of formula




wherein the definitions of substituents are given above, or


e) reacting a compound of formula



5 with a compound of formula




to a compound of formula




wherein the definitions of substituents are given above, or

10 f) reducing a compound of formula


9




to a compound of formula




wherein the definitions of substituents are given above, or  
 5 g) reacting a compound of formula




with a compound of formula




to a compound of formula




wherein the definition of substituents is given above, or  
h) reacting a compound of formula




5 with a compound of formula




to a compound of formula




wherein the definition of substituents is given above, or  
10 i) reacting a compound of formula



with a compound of formula



to a compound of formula



5

wherein the definition of substituents is given above, or

j) modifying one or more substituents R¹-R⁵ or R within the definitions given above, and

if desired, converting the compound obtained into a pharmaceutically acceptable acid

10 addition salt.

In accordance with process variant a) a compound of formula II, for example 3-amino-4-benzoylpyridine, is cooled in an ice bath and a compound of formula III, for example 2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl propionyl chloride in the presence of DIPEA (N-ethyl-diisopropyl-amine) in dichloromethane is added, and then the mixture is stirred at room temperature. The desired compound of formula I-1 is yielded after purification in good yields.

15

Process variant b) describes the reaction of a compound of formula IV with a compound of formula V to a compound of formula I-2. The reaction is carried out in

conventional manner, for example in a solvent, such as a mixture of toluene and triethylamine. The mixture is refluxed for about 1 hour.

- In accordance with process variant c) a compound of formula I-2 is reduced to a compound of formula I-4. This reaction is carried out with a reducing agent, such as
- 5 LiAlH<sub>4</sub> or BH<sub>3</sub>•THF, in conventional manner.

- Process variant d) describes the reaction of a compound of formula VI with a compound of formula VII to a compound of formula I-2. This reaction is carried out by deprotonation of a compound of formula VI with KHMDS (potassium hexamethyldisilazide) and subsequent addition of a compound of formula VII. A suitable
- 10 solvent is tetra-hydrofuran. The reaction is carried out at room temperature.

In accordance with process variant e) a compound of formula I-5 is prepared. This reaction is carried out by deprotonation of a compound of formula VIII with NaH and subsequent addition of a compound of formula VII. This reaction is carried out in conventional manner.

- 15 A further method for the preparation of a compound of formula I is described in process variant f). A compound of formula I-1 is reduced to a compound of formula I-3 in conventional manner, for example with LiAlH<sub>4</sub> or BH<sub>3</sub>•THF.

- In the process variant g) a compound of formula IX is activated with DCC (N,N'-dicyclohexylcarbodiimide) and DMAP (4-N,N-dimethylaminopyridine). Subsequent
- 20 addition of a compound of formula X yields a compound of formula I-6.

In accordance with variant h) a compound of formula IX is activated with CDI (1,1'-carbonyldiimidazole) and subsequent addition of a compound of formula V gives a compound of formula I-2.

- The process variant i) describes the process for preparation of a compound of formula I-1,
- 25 wherein a compound of formula XII is activated with CDI and subsequent addition of a compound of formula II yields a compound of formula I-13.

The salt formation is effected at room temperature in accordance with methods which are known per se and which are familiar to any person skilled in the art. Not only


salts with inorganic acids, but also salts with organic acids came into consideration. Hydrochlorides, hydrobromides, sulphates, nitrates, citrates, acetates, maleates, succinates, methan-sulphonates, p-toluenesulphonates and the like are examples of such salts.

The following schemes 1-7 describe the processes for preparation of compounds of formula I in more detail. The starting materials of formulae IX, X, XI, II, III, XII, XIII, XV, XVII, XVIII, XX, XXII, XXIV and XXV are known compounds or may be prepared according to methods known in the art.

In the schemes the following abbreviations have been used:


- DCC     N,N'-dicyclohexylcarbodiimide  
 10 DMAP     4-(N,N-dimethylamino)pyridine  
 CDI     1,1'-carbonyldiimidazole  
 KHMDS     potassium hexamethyldisilazide  
 DIPEA     N-ethyl-diisopropyl-amine  
 PivCl     pivaloyl chloride

Scheme 1




The substituents are given above.

Scheme 2



The substituents are given above.


Scheme 3



The definition of substituents is given above.




Scheme 4




The definition of substituents is given above.

Scheme 5




The definition of substituents is given above.

## Scheme 6



The definition of substituents is given above.

Scheme 7



R, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>5</sup> have the significances given above.

As mentioned earlier, the compounds of formula I and their pharmaceutically usable addition salts possess valuable pharmacological properties. It has been found that the compounds of the present invention are antagonists of the Neurokinin 1 (NK-1, substance P) receptor.

The compounds were investigated in accordance with the tests given hereinafter.

The affinity of test compounds for the NK1 receptor was evaluated at human NK1 receptors in CHO cells infected with the human NK1 receptor (using the Semliki virus expression system) and radiolabelled with [3H]substance P (final concentration 0.6 nM). Binding assays were performed in HEPES buffer (50 mM, pH 7.4) containing BSA (0.04 %) leupeptin (8 mg / ml), MnCl<sub>2</sub> (3mM) and phosphoramidon (2 mM). Binding assays

consisted of 250 ml of membrane suspension ( $1.25 \times 10^5$  cells / assay tube), 0.125 ml of buffer of displacing agent and 125 ml of [ $^3\text{H}$ ]substance P. Displacement curves were determined with at least seven concentrations of the compound. The assay tubes were incubated for 60 min at room temperature after which time the tube contents were rapidly  
5 filtered under vacuum through GF/C filters presoaked for 60 min with PEI (0.3%) with 2 x 2 ml washed of HEPES buffer (50 mM, pH 7.4). The radioactivity retained on the filters was measured by scintillation counting. All assays were performed in triplicate in at least 2 separate experiments.

The affinity to the NK-1 receptor, given as  $\text{pK}_i$ , is in the scope of 7,50 - 9,00 for the  
10 preferred compounds. Examples for such compounds are

N-(3,5-Bis-trifluoromethyl-benzyl)-N-methyl-6-morpholin-4-yl-4-phenoxy-nicotinamide	7,86
N-(3,5-Bis-trifluoromethyl-benzyl)-4-(2-chloro-phenoxy)-N-methyl-6-(4-methyl-piperazin-1-yl)-nicotinamide	8,42
N-(3,5-Bis-trifluoromethyl-benzyl)-N-methyl-6-morpholin-4-yl-4-o-tolyloxy-nicotinamide	8,56
N-(3,5-Bis-trifluoromethyl-benzyl)-4-(2-chloro-phenoxy)-N-methyl-6-morpholin-4-yl-nicotinamide	8,76

The compounds of formula I as well as their pharmaceutically usable acid addition salts can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions. The  
15 administration can, however, also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.

The compounds of formula I and their pharmaceutically usable acid addition salts can be processed with pharmaceutically inert, inorganic or organic excipients for the production of tablets, coated tablets, dragees and hard gelatine capsules. Lactose, corn  
20 starch or derivatives thereof, talc, stearic acid or its salts etc can be used as such excipients e.g. for tablets, dragées and hard gelatine capsules. Suitable excipients for soft gelatine capsules are e.g. vegetable oils, waxes, fats, semisolid and liquid polyols etc.

Suitable excipients for the manufacture of solutions and syrups are e.g. water,

polyols, saccharose, invert sugar, glucose etc.

Suitable excipients for injection solutions are e.g. water, alcohols, polyols, glycerol, vegetable oils etc.

Suitable excipients for suppositories are e.g. natural or hardened oils, waxes, fats,  
5 semi-liquid or liquid polyols etc.

Moreover, the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.

10 The dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, in the case of oral administration a daily dosage of about 10 to 1000 mg per person of a compound of general formula I should be appropriate, although the above upper limit can also be exceeded when necessary.

The following Examples illustrate the present invention without limiting it. All  
15 temperatures are given in degrees Celsius.

#### Example 1

N-(4-Benzoyl-pyridin-3-yl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide

a) N-(4-Benzoyl-pyridin-3-yl)-2-(3,5-bis-trifluoromethyl-phenyl)-isobutyramide

A solution of 397 mg (2 mmol) 3-amino-4-benzoylpyridine and 517 mg (4 mmol) N-  
20 ethyldiisopropylamine in 8 ml dichloromethane was cooled in an ice bath and a solution of 765 mg (2.4 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl chloride in 8 ml dichloromethane was added dropwise. The reaction mixture was warmed to room temperature and was stirred overnight. Water (5 ml) was added and the organic layer was separated. The aqueous phase was extracted with dichloromethane. The combined organic  
25 layers were dried (magnesium sulfate) and evaporated. The residue was purified by flash chromatography to give 235 mg (24%) of the title compound as orange oil.  
MS m/e (%): 481.3 (M+H<sup>+</sup>, 100).

b) N-(2-Benzoyl-4-chloro-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide

30 To a solution of 96 mg (0.2 mmol) of N-(4-benzoyl-pyridin-3-yl)-2-(3,5-bis-trifluoromethyl-phenyl)-isobutyramide in 1.2 ml of dimethylformamide were added 0.22 ml of a 1M potassium hexamethyldisilazide solution at 0°C. After 30 min 57 mg of methyl

iodide (0.4 mmol) were added and the reaction mixture was stirred at room temperature overnight. The solvent was evaporated, water and dichloromethane were added to the residue, the organic layer was separated and dried over magnesium sulfate. After evaporation of the solvent the product was purified by flash chromatography to yield 12 mg (12%) of the title compound as yellow oil.  
MS m/e (%): 495.2 (M+H<sup>+</sup>, 100).

### Example 2

N-(2-Benzoyl-4-chloro-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide

10 a) N-(2-Benzoyl-4-chloro-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-isobutyramide

To a solution of 233 mg (1 mmol) of 2-amino-5-chlorobenzophenone in 2 ml of 1,2-dichloroethane were added 360 mg (1.2 mmol) of 2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionic acid and the reaction mixture was shaken at 80°C for 1h. Dicyclohexyl carbodiimide (194 mg, 1.2 mmol) was added and shaking was continued overnight at the same temperature. The solvent was evaporated and the residue obtained was purified by column chromatography on silica gel to yield 298 mg (58%) of the title compound as yellow oil.

MS m/e (%): 514.2 (M+H<sup>+</sup>, 100)

20 b) N-(2-Benzoyl-4-chloro-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide

To a solution of 154 mg (0.3 mmol) of N-(2-benzoyl-4-chloro-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-isobutyramide in 1 ml dimethylformamide were added 26 mg (0.6 mmol) sodium hydride (55% suspension in mineral oil). After 30 min stirring at room temperature 85 mg of methyl iodide (0.6 mmol) were added and the reaction mixture was stirred at 80°C overnight. The solvent was evaporated under reduced pressure and the residue was purified by flash chromatography to yield 51 mg (32%) of the title compound as white crystals. M.p. 89-91°C.

MS m/e (%): 528.1 (M+H<sup>+</sup>, 100).

### Example 3

30 N-(2-Benzoyl-5-chloro-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide

The title compound was obtained as yellow oil in comparable yields according to the procedures described above for the preparation of N-(2-benzoyl-4-chloro-phenyl)-2-(3,5-

bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide using 2-amino-4-chlorobenzophenone instead of 2-amino-5-chlorobenzophenone.

MS m/e (%): 528.1 (M+H<sup>+</sup>, 100).

#### Example 4

5 N-(2-Benzoyl-3-chloro-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide

The title compound was obtained as yellowish oil in comparable yields according to the procedures described above for the preparation of N-(2-benzoyl-4-chloro-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide using 2-amino-6-

10 chlorobenzophenone instead of 2-amino-5-chlorobenzophenone.

MS m/e (%): 528.1 (M+H<sup>+</sup>, 100).

#### Example 5

2-(3,5-Bis-trifluoromethyl-phenyl)-N-[2-(3-chloro-benzoyl)-phenyl]-N-methyl-isobutyramide

15 The title compound was obtained as yellow oil in comparable yields according to the procedures described above for the preparation of N-(2-benzoyl-4-chloro-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide using 2-(3-chlorobenzoyl)-aniline instead of 2-amino-5-chlorobenzophenone.

MS m/e (%): 528.1 (M+H<sup>+</sup>, 100).

20

#### Example 6

N-(2-Benzoyl-6-methoxy-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide

The title compound was obtained as yellow oil in comparable yields according to the procedures described above for the preparation of N-(2-benzoyl-4-chloro-phenyl)-2-(3,5-

25 bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide using 2-amino-3-methoxybenzophenone instead of 2-amino-5-chlorobenzophenone.

MS m/e (%): 523.5 (M+H<sup>+</sup>, 100).

#### Example 7

N-(2-Benzoyl-4-methoxy-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-  
30 isobutyramide

The title compound was obtained as yellow oil in comparable yields according to the procedures described above for the preparation of N-(2-benzoyl-4-chloro-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide using 2-amino-5-methoxybenzophenone instead of 2-amino-5-chlorobenzophenone.

- 5 MS m/e (%): 523.5 (M+H<sup>+</sup>, 100).

#### Example 8

(RS)-2-(3,5-Bis-trifluoromethyl-phenyl)-N-[4-chloro-2-(2-chloro-phenylsulfanyl)-phenyl]-N-methyl-propionamide

- To a solution of 142 mg (0.5 mmol) of 1-chloro-4-methylamino-3-(2-chloro-phenylsulfanyl)-benzene in 2 ml of 1,2-dichloroethane were added 172 mg (0.6 mmol) of 2-(3,5-bis-trifluoromethyl-phenyl)-propionic acid and the reaction mixture was shaken at 80°C for 1h. Dicyclohexyl carbodiimide (97 mg, 0.6 mmol) was added and shaking was continued overnight at the same temperature. The solvent was evaporated and the residue obtained was purified by column chromatography on silica gel to yield 56 mg (20%) of the title compound as light yellow oil.

MS m/e (%): 551.9 (M+H<sup>+</sup>, 100), 553.9 (M+H<sup>+</sup>, 90).

#### Example 9

(RS)-N-(2-Benzoyl-4-chloro-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-propionamide

- 20 The title compound was obtained as yellow oil in comparable yields according to the procedures described above for the preparation of (RS)-2-(3,5-bis-trifluoromethyl-phenyl)-N-[4-chloro-2-(2-chloro-phenylsulfanyl)-phenyl]-N-methyl-propionamide using 2-methylamino-5-chlorobenzophenone instead of 1-chloro-4-methylamino-3-(2-chloro-phenylsulfanyl)-benzene.
- 25 MS m/e (%): 514.2 (M+H<sup>+</sup>, 100).

#### Example 10

N-[2-Benzoyl-4-(4-methyl-piperazin-1-yl)-phenyl]-2-(3,5-bis-trifluoromethyl-phenyl)-isobutyramide hydrochloride (1:1)

a) 2,2-Dimethyl-N-[4-(4-methyl-piperazin-1-yl)-phenyl]-propionamide

- 30 A solution of 5.58 g (29 mmol) 1-(4-aminophenyl)-4-methylpiperazine and 3.77 g (29 mmol) N-ethyl-diisopropylamine in 30 ml tetrahydrofuran was cooled in an ice bath and 3.518 g (29 mmol) pivaloyl chloride were added dropwise. The suspension was stirred for



18h at room temperature. Water (30 ml) and dichloromethane (50 ml) were added and the organic layer was separated. The aqueous phase was re-extracted with dichloromethane. The combined organic layers were dried (magnesium sulfate) and evaporated to give a white solid. Washing with a mixture of hexane and ethyl acetate (4:1) yielded 6.69 g (83%) of a white crystalline compound.  
MS m/e (%): 276.3 (M+H<sup>+</sup>, 100).

b) N-[2-Benzoyl-4-(4-methyl-piperazin-1-yl)-phenyl]-2,2-dimethyl-propionamide

A solution of 1.375 g (5 mmol) of 2,2-dimethyl-N-[4-(4-methyl-piperazin-1-yl)-phenyl]-propionamide was dissolved in 25 ml tetrahydrofuran and cooled to -70°C. Under argon 7.8 ml (12.5 mmol) of a 1.6 M n-butyl lithium solution in hexane was added slowly at this temperature. The cooling bath was removed and the mixture was stirred for 3 h at room temperature. The reaction mixture was cooled down again to -70°C and a solution of 1.234 g N-methoxy-N-methyl benzamide (7.2 mmol) in 5 ml tetrahydrofuran was added slowly at -70°C. After 10 min the cooling bath was removed and stirring was continued at room temperature for 1 hour. Water (50 ml) was added to quench the reaction and the mixture was extracted with diethylether (three times 50 ml). The organic layer was dried with magnesium sulfate and evaporated to give a brown oil, which was purified by flash chromatography with dichloromethane / methanol to yield 315 mg (17%) of the product as a light orange solid.  
MS m/e (%): 380.4 (M+H<sup>+</sup>, 100).

c) [2-Amino-5-(4-methyl-piperazin-1-yl)-phenyl]-phenyl-methanone

A solution of 0.3 g (0.8 mmol) of N-[2-benzoyl-4-(4-methyl-piperazin-1-yl)-phenyl]-2,2-dimethyl-propionamide in 10 ml of 3 N aqueous hydrochloric acid was stirred for 20h at room temperature. The reaction mixture was extracted once with ethyl acetate, the aqueous layer was made alkaline with concentrated sodium hydroxide solution and was extracted four times with dichloromethane. The combined organic layers were dried over magnesium sulfate and evaporated to yield 245 mg (quantitative) of the product as light yellow oil.  
MS m/e (%): 296.4 (M+H<sup>+</sup>, 100).

d) N-[2-Benzoyl-4-(4-methyl-piperazin-1-yl)-phenyl]-2-(3,5-bis-trifluoromethyl-phenyl)-isobutyramide hydrochloride

A solution of 200 mg (0.68 mmol) [2-amino-5-(4-methyl-piperazin-1-yl)-phenyl]-phenyl-methanone and 219 mg (1.69 mmol) N-ethyldiisopropylamine in 5 ml dichloromethane was cooled in an ice bath and a solution of 319 mg (1.0 mmol) 2-(3,5-bis-trifluoromethyl-

phenyl)-2-methyl-propionyl chloride in 2 ml dichloromethane was added dropwise. The reaction mixture was warmed to room temperature and was stirred for 3 hours. Water (5 ml) was added and the layers were separated. The aqueous phase was re-extracted with dichloromethane. The combined organic layers were dried (magnesium sulfate) and  
5 evaporated to give 50 mg of an oil. The residue was dissolved in 2 ml of ethyl acetate and 0.018 ml of a 4.75 N solution of hydrochloric acid in ethanol was added. After addition of 1 ml of diethylether the suspension was stirred for 15 min, the solid was filtered off and dried to give 24 mg (6%) of the title compound as a white solid.  
MS m/e (%): 578.1 (M+H<sup>+</sup>, 100).

10

## Example 11

4-Benzoyl-N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-nicotinamide hydrochloride (1:1)

a) 2-Chloro-5-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-pyridine hydrochloride

To 10 g (63.47 mmol) 2-chloropyridine-5-carboxylic acid were added 60 g (507 mmol)  
15 thionylchloride and the mixture was refluxed for 3 h. Excess thionylchloride was distilled off, ether (50 ml) was added and evaporated to remove traces of thionylchloride. The residue was dissolved in 30 ml dichloromethane and added dropwise to a solution of 11.88 g (0.133 mmol) 2-amino-2-methylpropanol in 30 ml dichloromethane at 0°C. The reaction mixture was stirred for 2 hours at room temperature and 30 ml water were added. The  
20 layers were separated and the aqueous phase was extracted again with dichloromethane. The combined organic layers were dried with magnesium sulfate and evaporated to yield an oily liquid. To the residue were added 22.6 g (190 mmol) of thionylchloride at 0°C and the mixture was stirred for 30 min. Ethyl acetate was added, the mixture was stirred for another 30 min and the crystals were washed with ethyl acetate and ether to yield 14 g  
25 (89%) of a white solid.  
MS m/e (%): 210 (M+H<sup>+</sup>, 10).

b) 1-[5-(4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-pyridin-2-yl]-4-methyl-piperazine2-Chloro-5-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-pyridine hydrochloride was transformed into its free base by dissolving 8.0 g (32 mmol) in saturated sodium bicarbonate solution  
30 and extracting the base into dichloromethane. The solvent was evaporated and the residue was dissolved in toluene. After addition of 11.35 g (113 mmol) N-methylpiperazine, the mixture was refluxed for 36 h. After cooling to room temperature water (50 ml) and ethyl acetate (150 ml) were added and the aqueous layer was extracted with ethyl acetate (150 ml). The combined organic layers were extracted two times with 1 N hydrochloric acid, the

acidic aqueous layer was made alkaline with 28% sodium hydroxide solution and extracted two times with dichloromethane. The organic layer was dried (magnesium sulfate) and evaporated. The residue was crystallized from ethyl acetate / hexane to yield 6.0 g (67%) of a white crystalline compound.

5 MS m/e (%): 274.1 ( $M+H^+$ , 100).

c) [5-(4,4-Dimethyl-4,5-dihydro-oxazol-2-yl)-2-(4-methyl-piperazin-1-yl)-pyridin-4-yl]-phenyl-methanone

2,2,6,6-Tetramethylpiperidine (0.932 g, 6.6 mmol) was placed in a three-necked flask. Under argon 10 ml of hexane were added, the solution was cooled to 0°C and n-butyl  
10 lithium (1.6 M solution in hexane) was added slowly. After stirring the yellow suspension for 10 min at 0°C, N,N,N',N'-tetramethylethylenediamine (767 mg, 6.6 mmol) was added. This mixture was added dropwise to a suspension of 1.65 g (6 mmol) of 1-[5-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-pyridin-2-yl]-4-methyl-piperazine in 20 ml of hexane at -78°. After stirring the yellow solution for 30 min at this temperature and for 45 min at  
15 0°C, a solution of 1.19 g N-methoxy-N-methyl benzamide (7.2 mmol) in 2 ml hexane / 2ml tetrahydrofuran was added slowly at 0°C. After 30 min, the cooling bath was removed and stirring was continued at room temperature overnight. Water was added and the mixture was extracted with ethyl acetate. The organic layer was dried (magnesium sulfate) and evaporated to give a brown oil, which was purified by flash chromatography with  
20 dichloromethane / methanol to yield 1.16 g (51%) of the product as a yellow solid.  
MS m/e (%): 379.5 ( $M+H^+$ , 100).

d) 4-Benzoyl-6-(4-methyl-piperazin-1-yl)-nicotinic acid 2-amino-2-methyl-propyl ester

To a solution of 1.13 g (3 mmol) [5-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-2-(4-methyl-piperazin-1-yl)-pyridin-4-yl]-phenyl-methanone in 30 ml tetrahydrofuran were added 3  
25 ml of 2 N aqueous hydrochloric acid and the reaction mixture was heated at 50°C for 18h. After cooling to room temperature, 1 N sodium hydroxide solution was added to adjust pH 11 and the mixture was extracted with ethyl acetate. The organic layer was dried (magnesium sulfate) and evaporated to yield 1.18 g (quantitative) of the product as yellow oil.

30 MS m/e (%): 481.4 ( $M+H^+$ , 100).

e) 4-Benzoyl-6-(4-methyl-piperazin-1-yl)-nicotinic acid

To a solution of 1.15 g (2.9 mmol) of 4-benzoyl-6-(4-methyl-piperazin-1-yl)-nicotinic acid 2-amino-2-methyl-propyl ester in 20 ml tetrahydrofuran were added dropwise 367 mg (3.05 mmol) pivaloyl chloride at 0°C. After stirring the light yellow suspension at the same

temperature for 1 hour, 1 M aqueous hydrochloric acid was added. Excess pivaloyl chloride was extracted with dichloromethane, the aqueous layer was made alkaline with 28 % sodium hydroxide solution and extracted twice with dichloromethane. The organic layer was dried (magnesium sulfate) and evaporated. The residue was dissolved in methanol, 1 M aqueous sodium hydroxide solution was added slowly at 0°C and the mixture was heated overnight at 65°C. Methanol was evaporated and the aqueous layer was adjusted to pH 5. The solvent was evaporated to yield the product contaminated with sodium chloride, which was used for the next step without further purification.

f) 4-Benzoyl-N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-nicotinamide hydrochloride (1:1)

A mixture of 4-benzoyl-6-(4-methyl-piperazin-1-yl)-nicotinic acid (1.5 mmol) from the last step and 3 ml of thionyl chloride were heated to 110°C for 1 hour. Excess of thionyl chloride was evaporated, the brown oil obtained was re-dissolved in ether and evaporated again to remove traces of thionyl chloride. The residue was dissolved in 2 ml of acetone and 1.16 g (4.5 mmol) (3,5-bis-trifluoromethylbenzyl)-methyl-amine were added. The mixture was stirred for 1.5 h at room temperature. The solvent was evaporated, dichloromethane and water were added and the aqueous layer was made alkaline with sodium hydroxide solution (28%). The organic layer was dried (magnesium sulfate), evaporated and purified by flash chromatography to yield 202 mg of an oil. This compound was dissolved in 5 ml diethyl ether and 0.075 ml of 4.75 N hydrochloric acid solution in ethanol were added. After stirring for 15 min the suspension was evaporated to dryness, re-suspended in 10 ml diethyl ether, filtered and dried to give 190 mg (21%) of the title compound as a white solid. M.p. 105°C, (decomp.). MS m/e (%): 565.2 (M+H<sup>+</sup>, 100).

25

### Example 12

N-(3,5-Bis-trifluoromethyl-benzyl)-4-(2-chloro-benzoyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-nicotinamide hydrochloride (1:1)

The title compound was obtained as white crystals in comparable yields according to the procedures described above for the preparation of 4-benzoyl-N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-nicotinamide hydrochloride (1:1 using N-methoxy-N-methyl 2-chloro-benzamide instead of N-methoxy-N-methyl benzamide in step c). M.p. 145°C, (decomp.). MS m/e (%): 599.1 (M+H<sup>+</sup>, 100).

## Example 13

## 2-Phenoxy-benzoic acid 3,5-bis-trifluoromethyl-benzyl ester

To a solution of 118 mg (0.55 mmol) 2-phenoxybenzoic acid and 122 mg (0.50 mmol) 3,5 bis(trifluoromethyl)benzyl alcohol in 1.5 ml dichloromethane at 0°C was added a solution  
5 of 124 mg (0.60 mmol) 1,3-dicyclohexylcarbodiimide and 7 mg (0.06 mmol) 4-dimethylaminopyridine in 1 ml dichloromethane. The ice bath was removed and stirring was continued at room temperature overnight. The solvent was removed *in vacuo* and the residue re-dissolved in diethyl ether, filtered and evaporated. The residue was purified by flash chromatography to give 70 mg (32%) of the title compound as white crystals.  
10 MS m/e (%): 440 (M<sup>+</sup>, 51), 347 (39), 227 (36), 197 (100).

## Example 14

## 2-Benzyl-N-(3,5-bis-trifluoromethyl-benzyl)-benzamide

To a solution of 255 mg (1.2 mmol) 2-benzylbenzoic acid in 1.5 ml tetrahydrofuran at 0°C were added 195 mg (1.2 mmol) 1,1'-carbonyldiimidazole. After stirring for 2.5 h at room  
15 temperature, a solution of 243 mg (1.0 mmol) 3,5 bis(trifluoromethyl)benzylamine in 0.5 ml tetrahydrofuran was added and stirring was continued overnight. The solvent was removed *in vacuo* and the residue was purified by flash chromatography to give 210 mg (49%) of the title compound as white crystals.  
MS m/e (%): 438 (M+H<sup>+</sup>, 100).

## Example 15

## 2-Benzyl-N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-benzamide

To a solution of 100 mg (0.23 mmol) 2-benzyl-N-(3,5-bis-trifluoromethyl-benzyl)-benzamide in 1 ml N,N-dimethylformamide at 0°C were added 50 mg (0.25 mmol) potassium hexamethyldisilazide. Stirring was continued for 1 h at this temperature and  
25 0.016 ml (0.25 mmol) methyl iodide were added. After stirring for 3 h at room temperature, ethyl acetate was added. The mixture was washed with brine, dried (magnesium sulfate) and evaporated. The solvent was removed *in vacuo* and the residue was purified by flash chromatography to give 90 mg (87%) of the title compound as a colourless oil.  
30 MS m/e (%): 452 (M+H<sup>+</sup>, 100).

## Example 16

N-(3,5-Bis-trifluoromethyl-benzyl)-N-methyl-2-(methyl-phenyl-amino)-benzamide

a) N-(3,5-Bis-trifluoromethyl-benzyl)-2-phenylamino-benzamide

The title compound was obtained as white crystals in comparable yield according to the  
5 procedure described above for the preparation of 2-benzyl-N-(3,5-bis-trifluoromethyl-benzyl)-benzamide.

MS m/e (%): 477 (M+K<sup>+</sup>, 24), 461 (M+Na<sup>+</sup>, 40), 439 (M+H<sup>+</sup>, 100).

b) 2-Benzyl-N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-benzamide

The title compound was obtained as a colourless oil in comparable yield according to the  
10 procedure described above for the preparation of 2-benzyl-N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-benzamide.

MS m/e (%): 505 (M+K<sup>+</sup>, 12), 489 (M+Na<sup>+</sup>, 19), 467 (M+H<sup>+</sup>, 100).

## Example 17

N-(2-Benzenesulfonyl-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-  
15 isobutyramide

a) N-(2-Benzenesulfonyl-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-isobutyramide

A solution of 233 mg (1.0 mmol) 2-aminophenyl phenyl sulfone and 0.25 ml (1.5 mmol)  
N-ethyl-diisopropylamine in 2 ml dichloromethane was cooled in an ice bath and a solution  
of 350 mg (1.1 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-propionyl chloride in  
20 1 ml dichloromethane was added dropwise. The reaction mixture was stirred at room  
temperature overnight, evaporated and the residue was purified by flash chromatography  
to give 490 mg (95%) of the title compound as a pale yellow oil.

MS m/e (%): 533 (M+NH<sub>4</sub><sup>+</sup>, 60), 516 (M+H<sup>+</sup>, 100).

b) N-(2-Benzenesulfonyl-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-  
25 isobutyramide

The title compound was obtained as a colourless oil in comparable yield according to the  
procedure described above for the preparation of 2-benzyl-N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-benzamide.

MS m/e (%): 552 (M+Na<sup>+</sup>, 40), 530 (M+H<sup>+</sup>, 100).

30

## Example 18

2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(2-phenoxy-phenyl)-isobutyramide

The title compound was obtained as a colourless oil in comparable yield according to the procedures described above for the preparation of N-(2-benzenesulfonyl-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide using 2-phenoxyaniline instead of 2-aminophenyl phenyl sulfone.

5 MS m/e (%): 482 (M+H<sup>+</sup>, 100).

#### Example 19

N-(2-Benzyl-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide

The title compound was obtained as a colourless oil in comparable yield according to the procedures described above for the preparation of N-(2-benzenesulfonyl-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide using 2-benzylaniline instead of 2-aminophenyl phenyl sulfone.

10 MS m/e (%): 480 (M+H<sup>+</sup>, 100).

#### Example 20

2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(2-o-tolyloxy-phenyl)-isobutyramide

15 The title compound was obtained as pale yellow crystals in comparable yield according to the procedures described above for the preparation of N-(2-benzenesulfonyl-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide using 2-(o-tolyloxy)aniline instead of 2-aminophenyl phenyl sulfone.

MS m/e (%): 496 (M+H<sup>+</sup>, 100).

20

#### Example 21

N-(2-Benzoyl-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide

The title compound was obtained as a pale yellow oil in comparable yield according to the procedures described above for the preparation of N-(2-benzenesulfonyl-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide using 2-aminobenzophenone

25 instead of 2-aminophenyl phenyl sulfone.

MS m/e (%): 516 (M+Na<sup>+</sup>, 55), 494 (M+H<sup>+</sup>, 100).

#### Example 22

2-(3,5-Bis-trifluoromethyl-phenyl)-N-[2-(2,4-dichloro-phenoxy)-phenyl]-N-methyl-isobutyramide

30 The title compound was obtained as a colourless foam in comparable yield according to the procedures described above for the preparation of N-(2-benzenesulfonyl-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide using 2-(2,4-

dichlorophenoxy)aniline instead of 2-aminophenyl phenyl sulfone.

MS m/e (%): 549 ( $M^+$ , 4), 530 (21), 388 (100).

#### Example 23

2-(3,5-Bis-trifluoromethyl-phenyl)-N-(2-phenylsulfanyl-phenyl)-isobutyramide

- 5 The title compound was obtained as a pale yellow oil in comparable yield according to the procedure described above for the preparation of N-(2-benzenesulfonyl-phenyl)-2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-isobutyramide using 2-aminophenyl phenyl sulfide instead of 2-aminophenyl phenyl sulfone. Step b) was not performed.

MS m/e (%): 484 ( $M+H^+$ , 100).

10

#### Example 24

2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-[2-(methyl-phenyl-amino)-phenyl]-propionamide

a) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-(2-phenylamino-phenyl)-acetamide

- 15 To a solution of 545 mg (2.0 mmol) 3,5-bis(trifluoromethyl)phenylacetic acid in 2 ml tetrahydrofuran at 0°C were added 325 mg (2.0 mmol) 1,1'-carbonyldiimidazole. After stirring for 2.5 h at room temperature, 305 mg (1.66 mmol) 2-aminodiphenylamine were added and stirring was continued for 8h at 60°C. The solvent was removed *in vacuo* and the residue was purified by flash chromatography to give 480 mg (66%) of the title compound as white crystals.

- 20 MS m/e (%): 439 ( $M+H^+$ , 35), 142 (100).

b) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-[2-(methyl-phenyl-amino)-phenyl]-propionamide

- 25 To a solution of 389 mg (0.89 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-(2-phenylamino-phenyl)-acetamide in 1 ml N,N-dimethylformamide at 0°C were added 560 mg (2.66 mmol) potassium hexamethyldisilazide. Stirring was continued for 1 h at this temperature and 510 mg (2.66 mmol) methyl iodide were added. After stirring for 3 h at room temperature, ethyl acetate was added. The mixture was washed with brine, dried (magnesium sulfate) and evaporated. The solvent was removed *in vacuo* and the residue was purified by flash chromatography to give 110 mg (25%) of the title compound as white crystals.
- 30

MS m/e (%): 480 ( $M^+$ , 76), 239 (100).



## Example 25

**2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-[2-(methyl-phenyl-amino)-phenyl]-isobutyramide**

To a solution of 52 mg (0.11 mmol) 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-[2-(methyl-phenyl-amino)-phenyl]-propionamide in 0.5 ml N,N-dimethylformamide at 0°C were added 32 mg (0.16 mmol) potassium hexamethyldisilazide. Stirring was continued for 1 h at this temperature and 30 mg (0.16 mmol) methyl iodide were added. After stirring for 3 h at room temperature, ethyl acetate was added. The mixture was washed with brine, dried (magnesium sulfate) and evaporated. The solvent was removed *in vacuo* and the residue was purified by flash chromatography to give 54 mg (quantitative) of the title compound as colourless oil.

MS m/e (%): 494 ( $M^+$ , 87), 195 (100).

## Example 26

**2-(3,5-Bis-trifluoromethyl-phenyl)-N-[2-(methyl-phenyl-amino)-phenyl]-acetamide**

The title compound was obtained as white crystals in comparable yield according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-[2-(methyl-phenyl-amino)-phenyl]-propionamide using N-methyl-N-phenyl-benzene-1,2-diamine instead of 2-aminodiphenylamine. Step b) was not performed.

MS m/e (%): 453 ( $M+H^+$ , 100).

## Example 27

**2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-[2-(methyl-phenyl-amino)-phenyl]-acetamide**

The title compound was obtained as a colourless oil in comparable yield according to the procedure described above for the preparation of 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-[2-(methyl-phenyl-amino)-phenyl]-propionamide using N,N'-dimethyl-N-phenyl-benzene-1,2-diamine instead of 2-aminodiphenylamine. Step b) was not performed.

MS m/e (%): 467 ( $M+H^+$ , 100).

## Example 28

**N-(3,5-Bis-trifluoromethyl-benzyl)-N-methyl-6-morpholin-4-yl-4-phenoxy-nicotinamide**

a) 6-Chloro-4-phenoxy-nicotinic acid ethyl ester

To a solution of 196 mg (ca. 4 mmol) sodium hydride dispersion in mineral oil (ca. 50%) in 15 ml N,N-dimethylformamide a solution of 385 mg (4.09 mmol) phenol in 10 ml N,N-dimethylformamide was added dropwise at room temperature under argon. After 15 min. this solution was slowly added via cannula to a solution of 4,6-dichloro-nicotinic acid ethyl ester in 20 ml N,N-dimethylformamide at room temperature. After 2h the reaction was quenched with 20 ml water. The mixture was extracted with 3 50-ml portions of ethyl acetate. The combined organic extracts were dried with sodium sulfate and concentrated. After drying in high vacuo at 50°C and flash column chromatography 800 mg (70.4%) of the title compound was obtained as a white solid. As a side product 130 mg (11.4%) 4-chloro-6-phenoxy-nicotinic acid ethyl ester were also isolated.

MS m/e (%): 277 ( $M^+$ , 81), 232 ( $[M-OEt]^+$ , 100).

b) 6-Morpholin-4-yl-4-phenoxy-nicotinic acid ethyl ester

A solution of 130 mg (0.468 mmol) 6-chloro-4-phenoxy-nicotinic acid ethyl ester, 0.040 ml (0.47 mmol) morpholine and 0.065 ml (0.47 mmol) triethylamine in 7 ml tetrahydrofuran was stirred at reflux for 40h. After cooling to room temperature the reaction mixture was filtered, diluted with ethyl acetate and washed with water and saturated aqueous sodium chloride solution. The organic layer was dried with sodium sulfate and concentrated. Flash column chromatography afforded 66 mg (43%) of the title compound as a white solid.

MS m/e (%): 329 ( $M+H^+$ , 100).

c) 6-Morpholin-4-yl-4-phenoxy-nicotinic acid

A mixture of 66 mg (0.20 mmol) 6-morpholin-4-yl-4-phenoxy-nicotinic acid ethyl ester, 2 ml methanol and 2 ml 1N aqueous sodium hydroxide solution was stirred at room temperature for 1h. The reaction mixture was diluted with water and washed with tert-butyl-methyl-ether. The aqueous layer was acidified to pH 4-5 with concentrated hydrochloric acid solution and extracted with 3 portions of dichloromethane. The combined organic layers were washed with saturated aqueous sodium chloride solution and dried with sodium sulfate. Concentration afforded 46 mg (77%) of the title compound as a white solid.

MS m/e (%): 301 ( $M+H^+$ , 100).

d) N-(3,5-Bis-trifluoromethyl-benzyl)-N-methyl-6-morpholin-4-yl-4-phenoxy-nicotinamide

- A mixture of 46 mg (0.15 mmol) 6-morpholin-4-yl-4-phenoxy-nicotinic acid, 43 mg (0.17 mmol) (3,5-bis-trifluoromethyl-benzyl)-methylamine, 32 mg (0.17 mmol) 1-(3-diaminopropyl)-3-ethyl-carbodiimide hydrochloride and a catalytic amount of 4-(N,N-dimethylamino)-pyridine in 3 ml dichloromethane was stirred at room temperature over night. The reaction mixture was diluted with water, adjusted to pH 6 with saturated aqueous ammonium chloride solution and extracted with dichloromethane. The combined organic layers were washed with saturated aqueous sodium chloride solution, dried with sodium sulfate and concentrated. Flash column chromatography afforded 68 mg (83%) of the title compound as a white solid.
- MS m/e (%): 540 (M+H<sup>+</sup>, 100).

#### Example 29

N-(3,5-Bis-trifluoromethyl-benzyl)-4-(2-chloro-phenoxy)-N-methyl-6-morpholin-4-yl-nicotinamide

- The title compound was obtained as a white solid in comparable yields according to the procedures described above for the preparation of N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-morpholin-4-yl-4-phenoxy-nicotinamide (Example 28) using 2-chlorophenol instead of phenol in step a).
- MS m/e (%): 574 (M+H<sup>+</sup>, 100).

#### Example 30

- N-(3,5-Bis-trifluoromethyl-benzyl)-4-(2-chloro-phenoxy)-N-methyl-6-(4-methyl-piperazin-1-yl)-nicotinamide

- The title compound was obtained as a white solid in comparable yields according to the procedures described above for the preparation of N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-morpholin-4-yl-4-phenoxy-nicotinamide (Example 28) using 2-chlorophenol instead of phenol in step a) and 1-methylpiperazine instead of morpholine in step b).
- MS m/e (%): 587 (M+H<sup>+</sup>, 100).

#### Example 31

N-(3,5-Bis-trifluoromethyl-benzyl)-N-methyl-6-morpholin-4-yl-4-o-tolyloxy-nicotinamide

- The title compound was obtained as a white solid in comparable yields according to the procedures described above for the preparation N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-morpholin-4-yl-4-phenoxy-nicotinamide (Example 28) using o-cresol instead of phenol in step a).

MS m/e (%): 554 (M+H<sup>+</sup>, 100).

#### Example A

Tablets of the following composition are manufactured in the usual manner:

	mg/tablet
5 Active substance	5
Lactose	45
Corn Starch	15
Microcrystalline cellulose	34
Magnesium stearat	1
10	Tablet weight: 100

#### Example B

Capsules of the following composition are manufactured:

	mg/capsule
Active substance	10
15 Lactose	155
Corn starch	30
Talc	5
	Capsule fill weight: 200

20 The active substance, lactose and corn starch are firstly mixed in a mixer and then in a comminuting machine. The mixture is returned to the mixer, the talc is added thereto and mixed thoroughly. The mixture is filled by machine into hard gelatine capsules.

#### Example C


	mg/supp.
Suppositories of the following composition are manufactured:	
Active substance	15
25 Suppository mass	1285
	Total 1300

The suppository mass is melted in a glass or steel vessel, mixed thoroughly and cooled to 45°C. Thereupon, the finely powdered active substance is added thereto and stirred until it has dispersed completely. The mixture is poured into suppository moulds of suitable size,

left to cool, the suppositories are then removed from the moulds and packed individually in wax paper or metal foil.


Claims

## 1. Compounds of the general formula



5 wherein

R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl;

R<sup>1</sup> is hydrogen or halogen; orR and R<sup>1</sup> may be together  $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$ ;R<sup>2</sup> is hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano;10 R<sup>3</sup> is independently from each other hydrogen, lower alkyl or form a cycloalkyl group;R<sup>4</sup> is hydrogen, halogen, lower alkyl, lower alkoxy,  $-\text{N}(\text{R}^5)_2$ ,  $-\text{N}(\text{R}^5)\text{S}(\text{O})_2$ -lower alkyl,  $-\text{N}(\text{R}^5)\text{C}(\text{O})\text{R}^5$  or a cyclic tertiary amine of the group15 R<sup>5</sup> is, independently from each other, hydrogen, C<sub>3-6</sub>-cycloalkyl, benzyl or lower alkyl;R<sup>6</sup> is hydrogen, hydroxy, lower alkyl,  $-\text{N}(\text{R}^5)\text{CO}$ -lower alkyl, hydroxy-lower alkyl, cyano,  $-\text{CHO}$  or a 5- or 6 membered heterocyclic group, optionally bonded via an alkylene group,20 X is  $-\text{C}(\text{O})\text{N}(\text{R}^5)-$ ,  $-(\text{CH}_2)_m\text{O}-$ ,  $-(\text{CH}_2)_m\text{N}(\text{R}^5)-$ ,  $-\text{N}(\text{R}^5)\text{C}(\text{O})-$ ,  $-\text{C}(\text{O})\text{O}-$  or  $-\text{N}(\text{R}^5)(\text{CH}_2)_m-$ ;

Y is  $-(CH_2)_n-$ ,  $-O-$ ,  $-S-$ ,  $-SO_2-$ ,  $-C(O)-$  or  $-N(R^5)-$ ;

Z is  $=N-$ ,  $-CH=$  or  $-C(Cl)=$ ;

n is 0 - 4; and

m is 1 or 2;

5 and pharmaceutically acceptable acid addition salts thereof.

2. A compound according to claim 1, wherein Y is  $-C(O)-$  and  $R^4$  is 4-methylpiperazinyl.

3. A compound according to claim 2, which is


10 N-[2-Benzoyl-4-(4-methyl-piperazin-1-yl)-phenyl]-2-(3,5-bis-trifluoromethyl-phenyl)isobutyramide,  
4-Benzoyl-N-(3,5-bis-trifluoromethyl-benzyl)-N-methyl-6-(4-methyl-piperazin-1-yl)-nicotinamide and  
N-(3,5-Bis-trifluoromethyl-benzyl)-4-(2-chloro-benzoyl)-N-methyl-6-(4-methyl-piperazin-1-yl)nicotinamide.

15 4. A compound according to claim 1, wherein Y is  $-O-$ , and  $R^4$  is hydrogen, 4-methylpiperazinyl or morpholinyl.


5. A compound according to claim 4, which is

2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(2-phenoxy-phenyl)-isobutyramide,  
20 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(2-o-tolyloxy-phenyl)-isobutyramide,  
2-(3,5-Bis-trifluoromethyl-phenyl)-N-[2-(2,4-dichloro-phenoxy)-phenyl]-N-methyl-isobutyramide.  
N-(3,5-Bis-trifluoromethyl-benzyl)-N-methyl-6-morpholin-4-yl-4-phenoxy-  
25 nicotinamide,  
N-(3,5-Bis-trifluoromethyl-benzyl)-4-(2-chloro-phenoxy)-N-methyl-6-morpholin-4-yl-nicotinamide,  
N-(3,5-Bis-trifluoromethyl-benzyl)-4-(2-chloro-phenoxy)-N-methyl-6-(4-methyl-piperazin-1-yl)-nicotinamide and  
30 N-(3,5-Bis-trifluoromethyl-benzyl)-N-methyl-6-morpholin-4-yl-4-o-tolyloxy-nicotinamide.

6. A compound according to claim 1, wherein Y is  $-N(CH_3)-$  and  $R^4$  is hydrogen.
7. A compound according to claim 6, which is
- 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-[2-(methyl-phenyl-amino)-phenyl]-propionamide,
- 5 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-[2-(methyl-phenyl-amino)-phenyl]-isobutyramide,
- 2-(3,5-Bis-trifluoromethyl-phenyl)-N-[2-(methyl-phenyl-amino)-phenyl]-acetamide and
- 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-[2-(methyl-phenyl-amino)-phenyl]-acetamide.
- 10 8. A medicament containing one or more compounds as claimed in any one of claims 1-7 and pharmaceutically acceptable excipients.
9. A medicament according to claim 8 for the treatment of diseases related to the NK-1 receptor antagonists.
- 15 10. A process for preparing a compound of formula I as defined in claim 1, which process comprises
- a) reacting a compound of formula



with a compound of formula




20

to a compound of formula




39




wherein  $R^1$  -  $R^5$ ,  $R$ ,  $Y$ ,  $Z$  and  $n$  have the significances given in claim 1,  
or

b) reacting a compound of formula




5

with a compound of formula




to give a compound of formula




10 wherein  $R^1$  -  $R^5$ ,  $R$ ,  $Z$ ,  $Y$  and  $n$  have the significances given in claim 1, or

c) reducing a compound of formula




to a compound of formula




wherein the definitions of substituents are given in claim 1,

5 or


d) reacting a compound of formula



with a compound of formula




10 to a compound of formula



wherein the definitions of substituents are given in claim 1,


or

e) reacting a compound of formula




5

with a compound of formula



to a compound of formula




10


wherein the definitions of substituents are given in claim 1,

or

reducing a compound of formula




to a compound of formula




wherein the definitions of substituents are given in claim 1,

5 or


g) reacting a compound of formula



with a compound of formula




10 to a compound of formula



wherein the definition of substituents is given in claim 1,


or

h) reacting a compound of formula




5

with a compound of formula




to a compound of formula




10 wherein the definitions of substituents is given in claim 1,

or


i) reacting a compound of formula



with a compound of formula



to a compound of formula



5

wherein the definitions of substituents is given in claim 1,

or

j) modifying one or more substituents R¹-R⁵ or R within the definitions given above,  
and

10 if desired, converting the compound obtained into a pharmaceutically acceptable acid  
addition salt.

11. A compound according to any one of claims 1-7, whenever prepared by a process  
as claimed in claim 10 or by an equivalent method.

12. The use of a compound in any one of claims 1-7 for the treatment of diseases.

15 13. The use of a compound in any one of claims 1-7 for the treatment of diseases  
related to the NK-1 receptor.

14. The use of a compound of formula I in accordance with claims 1 - 7 for the manufacture of a medicament containing a compound of formula I for the treatment of diseases related to the NK-1 receptor.

15. The invention as hereinbefore described.

(19) World Intellectual Property Organization  
International Bureau




(43) International Publication Date  
31 August 2000 (31.08.2000)

PCT


(10) International Publication Number  
**WO 00/50398 A3**

- (51) International Patent Classification<sup>7</sup>: C07D 213/75, C07C 233/29, C07D 295/12, A61K 31/44, 31/167, A61P 25/00
- (21) International Application Number: PCT/EP00/01224
- (22) International Filing Date: 15 February 2000 (15.02.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
99103502.3 24 February 1999 (24.02.1999) EP
- (71) Applicant: F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).
- (74) Agent: POPPE, Regina; Grenzacherstrasse 124, CH-4070 Basel (CH).
- (81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (72) Inventors: BOES, Michael; 3550 Jeanne Mance, App. E 1906, Montreal, Quebec H2X 3P7 (CA). GALLEY, Guido; Katzenbuckweg 14, D-79618 Rheinfelden (DE). GODEL, Thierry; Mittlere Strasse 7, CH-4056 Basel (CH). HOFFMANN, Torsten; Muttenerstrasse 71, CH-4127 Birsfelden (CH). HUNKELER, Walter; Im Stigler 32, CH-4312 Magden (CH). SCHNIDER, Patrick; Stallnenrain 7, CH-4104 Oberwil (CH). STADLER, Heinz; Waldhofstrasse 37, CH-4310 Rheinfelden (CH).
- Published:  
— With international search report.
- (88) Date of publication of the international search report:  
5 April 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHENYL- AND PYRIDINYL DERIVATIVES AS NEUROKININ 1 ANTAGONISTS



(I)



(a)

WO 00/50398 A3

is hydrogen, halogen, lower alkyl, lower alkoxy, -N(R<sup>5</sup>)<sub>2</sub>, -N(R<sup>5</sup>)S(O)<sub>2</sub>-lower alkyl, -N(R<sup>5</sup>)C(O)R<sup>5</sup> or a cyclic tertiary amine of the group (a); R<sup>5</sup> is, independently from each other, hydrogen, C<sub>3-6</sub>-cycloalkyl, benzyl or lower alkyl; R<sup>6</sup> is hydrogen, hydroxy, lower alkyl, -N(R<sup>5</sup>)CO-lower alkyl, hydroxy-lower alkyl, cyano, -CHO or a 5- or 6 membered heterocyclic group, optionally bonded via an alkylene group, X is -C(O)N(R<sup>5</sup>)-, -(CH<sub>2</sub>)<sub>m</sub>O-, -(CH<sub>2</sub>)<sub>m</sub>N(R<sup>5</sup>)-, -N(R<sup>5</sup>)C(O)-, C(O)O- or -N(R<sup>5</sup>)(CH<sub>2</sub>)<sub>m</sub>-; Y is -(CH<sub>2</sub>)<sub>n</sub>-, -O-, -S-, SO<sub>2</sub>-, -C(O)- or -N(R<sup>5</sup>)-; Z is =N-, -CH= or -C(Cl)=; n is 0-4; and, is 1 or 2; and to pharmaceutically acceptable acid addition salts thereof. It has been shown that the compounds of formula (I) have a high affinity to the NK-1 receptor.

(57) Abstract: The invention relates to compounds of general formula (I), wherein R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; R<sup>1</sup> is hydrogen or halogen; or R and R<sup>1</sup> may be together -CH=CH-CH=CH-; R<sup>2</sup> is hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; R<sup>3</sup> is independently from each other hydrogen, lower alkyl or form a cycloalkyl group; R<sup>4</sup>



In **itional Application No**

PCT/EP 00/01224

### A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D213/75 C07C233/29 C07D295/12 A61K31/44 A61K31/167  
A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

**Minimum documentation searched (classification system followed by classification symbols)**

IPC 7 C07D C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**EPO-Internal, CHEM ABS Data**

### C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E, L	<p>WO 00 53572 A (HOFFMANN LA ROCHE)  14 September 2000 (2000-09-14)  " L: Priority of the present application  may not be valid for subject matter which  is already covered by the cited earlier  application"  the whole document</p>	1,8-14
E, L	<p>DE 100 08 042 A (HOFFMANN LA ROCHE)  31 August 2000 (2000-08-31)  " L: Priority of the present application  may not be valid for subject matter which  is already covered by the cited earlier  application"  the whole document</p>	1,8-14

-/-

**X** Further documents are listed in the continuation of box C.

**Y** Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T"** later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X"** document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y"** document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "Z"** document member of the same patent family

Date of the actual completion of the international search

**6 November 2000**

Date of mailing of the international search report

**20/11/2000**

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer \_\_\_\_\_

Seitner, I

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/01224

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 00 40237 A (BRIDGES ALEXANDER JAMES ;DUDLEY DAVID THOMAS (US); GRACHEK STEPHE) 13 July 2000 (2000-07-13) page 7, line 17	1,8,12
P,X	DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SCHLITZER, MARTIN ET AL: "Different amino acid replacements in CAAX-tetrapeptide based peptidomimetic farnesyltransferase inhibitors" retrieved from STN Database accession no. 130:320375 XP002151988 * CAS RN 76303-78-1: N-(2-benzoyl-4-chlorophenyl)-benzeneacetam ide * & ARCH. PHARM. (WEINHEIM, GER.) (1999), 332(4), 124-132 ,	1,8,12
X	WO 99 01421 A (DOHERTY ANNETTE MARIAN ;BARRETT STEPHEN DOUGLAS (US); BRIDGES ALEX) 14 January 1999 (1999-01-14) example 68	1,8,12
X	WO 97 31635 A (LILLY CO ELI ;GITTER BRUCE D (US); IYENGAR SMRITI (US)) 4 September 1997 (1997-09-04) example 3	1,8,12
X	US 3 112 356 A (DU PONT DE NEMOURS AND COMPANY) 26 November 1963 (1963-11-26) example C	1
A	WO 95 16679 A (LADDUWAHETTY TAMARA ;WILLIAMS BRIAN JOHN (GB); CHAMBERS MARK STUAR) 22 June 1995 (1995-06-22) cited in the application page 38, paragraph 1	1,8,9, 12-14

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/01224

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0053572	A	14-09-2000	NONE	
DE 10008042	A	31-08-2000	AU 1946800 A	31-08-2000
			BR 0000908 A	12-09-2000
			EP 1035115 A	13-09-2000
			FR 2790473 A	08-09-2000
			GB 2347422 A	06-09-2000
			NO 20000885 A	25-08-2000
			PL 338598 A	28-08-2000
WO 0040237	A	13-07-2000	AU 2203800 A	24-07-2000
WO 9901421	A	14-01-1999	AU 8262698 A	25-01-1999
			BR 9810385 A	05-09-2000
			EP 0993437 A	19-04-2000
			HR 980369 A	30-04-1999
			ZA 9805726 A	27-01-1999
WO 9731635	A	04-09-1997	AU 2139097 A	16-09-1997
US 3112356	A	26-11-1963	NONE	
WO 9516679	A	22-06-1995	AT 194336 T	15-07-2000
			AU 701862 B	04-02-1999
			AU 1437595 A	03-07-1995
			BG 100715 A	31-01-1997
			BR 9408351 A	26-08-1997
			CA 2178949 A	22-06-1995
			CN 1142819 A, B	12-02-1997
			CZ 9601772 A	11-12-1996
			DE 69425161 D	10-08-2000
			EP 0734381 A	02-10-1996
			ES 2147840 T	01-10-2000
			FI 962489 A	13-08-1996
			HR 941000 A	30-06-1997
			HU 76476 A	29-09-1997
			JP 9506628 T	30-06-1997
			LV 11617 A	20-12-1996
			LV 11617 B	20-04-1997
			NO 962523 A	16-08-1996
			NZ 278222 A	27-05-1998
			PL 315153 A	14-10-1996
			SK 75396 A	04-12-1996
			US 5637699 A	10-06-1997
			US 5719147 A	17-02-1998
			US 5872116 A	16-02-1999
			US 5922706 A	13-07-1999
			ZA 9410008 A	15-07-1996

